Acute cholangitis is a severe, bacterial infection of the biliary tract precipitated by an obstruction that often results in systemic inflammation and, in some cases, life‐threatening sepsis. This ...
The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer. Approval stipulates use in unresectable or ...
Patients with advanced biliary tract cancer can safely use antibiotics while benefiting from treatment with durvalumab plus gemcitabine and cisplatin, according to study results presented at ASCO ...
Keytruda, combined with gemcitabine and cisplatin, is approved for advanced biliary tract cancer, showing a 17% reduction in death risk compared to chemotherapy alone. The KEYNOTE-966 trial indicated ...
The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer. The FDA has approved pembrolizumab (Keytruda; Merck ...
Bile duct cancer, also known as cholangiocarcinoma, is a rare cancer of the bile ducts. The bile ducts carry bile from the liver to the small intestine, where it helps in the digestion of the fats in ...
Neonatal hepatitis (NH) and biliary atresia are two separate conditions that share specific symptoms. Both conditions affect newborn infants and can cause liver damage. Bile is a substance the liver ...
Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results